live attenuated monovalent dengue virus vaccine (rDEN3∆30) / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model. (PubMed, N Engl J Med) - P2 | "In a controlled human infection model, a high daily dose of oral mosnodenvir led to a significantly lower DENV-3 RNA load than placebo. Mosnodenvir did not result in any serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases and Johnson & Johnson; ClinicalTrials.gov number, NCT05048875.)."

Clinical • Journal • Allergy • Dengue Fever • Immunology • Infectious Disease

Phase 1 trial to safely model primary, secondary, and tertiary dengue (ASTMH 2025) - P1 | "In ongoing work, we are measuring CD4+ and CD8+ T cell profiles with activation-induced marker and intracellular cytokine staining assays, antibody-dependent enhancement titers, and envelope-dimer epitope antibodies. This study informs how prior exposure increases viremia and immunity becomes protective against dengue."

P1 data • Dengue Fever • Infectious Disease • CD4 • CD8

Phase 1 trial to model primary, secondary, and tertiary dengue infection using a monovalent vaccine (ASTMH 2024) - P1 | "We are conducting a partially blinded phase I vaccine trial (NCT05691530) to examine how natural immunity influences the signs and symptoms, viremia, and immune responses to a dengue vaccine...Ongoing work will evaluate neutrophil and T cell responses, and germinal center changes using sequential fine needle lymph node aspirates. This study will elucidate the immunological factors driving the induction of cross-serotypic protective immunity, inform correlates of protection, and highlight potential therapeutic targets."

P1 data • Dengue Fever • Infectious Disease

Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine. (PubMed, BMC Infect Dis) - P1 | "This trial will compare the immune responses after primary, secondary, and tertiary DENV exposure in naturally infected humans living in non-endemic areas. By evaluating dengue vaccines in a new population and modeling the induction of cross-serotypic immunity, this work may inform vaccine evaluation and broaden potential target populations."

Journal • P1 data • Dengue Fever • Infectious Disease